Nerve growth factor (NGF) plays an important role in neuronal trophism of the central nervous system. Since NGF has been shown to influence the survival of cholinergic neurons in the basal forebrain, a potential use of NGF has been suggested for the therapy of neurodegenerative diseases. However, NGF is known to poorly cross the blood brain barrier, therefore, the direct use of NGF as a therapeutic tool is limited. Since NGF is already produced in the brain, the use of pharmacological agents that enhance NGF biosynthesis becomes a crucial alternative. To this end, it is essential to learn whether NGF biosynthesis can be pharmacological regulated in the brain. It has been shown that different pharmacological stimuli that activate cAMP formation, including beta-adrenergic receptor (BAR) simulation, induce synthesis and release of NGF from C6 rat glioma cells or normal astrocytes in culture. These findings suggest that noradrenaline can regulate NGF biosynthesis in astrocytes. However, before inferring that these results reflect a mechanism of physiological significance, it is necessary to investigate whether BAR stimulation enhances NGF biosynthesis in the brain. This hypothesis will be tested in this proposal by measuring changes in the biosynthesis of NGF in different brain regions of rats, after acute and chronic (2 weeks, 1 month) administration of clenbuterol, a lipophilic BAR agonist. Moreover, other specific alpha- and beta-noradrenergic receptor agonists and antagonists will be used to characterize the specificity of clenbuterol's effect. NGF biosynthesis will be estimated by measure NGF mRNA content, by a quantitative Northern blot analysis, and NGF content, by a two site enzyme immunoassay (ELISA). 21 day old, young adult (3 months) and aged (2 year old) rats will be used to establish whether BAR stimulation enhances NGF biosynthesis in the brain throughout life. These studies will be combined with those aimed to establish whether NGF, pharmacological induced, exerts a physiological effect on the forebrain cholinergic system. To this end, after the pharmacological treatments, choline acetyltransferase (ChAT) activity and immunohistochemistry will be determined, together with NGF receptor (mRNA and protein), in rats of different ages. Finally, C6 rat glioma cells will be used to investigate whether other signal transduction mechanisms (protein kinase C activation and steroids) are operative in the regulation of NGF biosynthesis. It is the ultimate goal of this project to supply significant new information concerning mechanisms regulating NGF biosynthesis which could be used to gain further knowledge on the physiological importance of NGF in the brain and to develop new therapeutic tolls for the treatment of neuronal degeneration.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS029664-03
Application #
2267785
Study Section
Neurological Sciences Subcommittee 1 (NLS)
Project Start
1991-08-06
Project End
1995-09-29
Budget Start
1993-08-01
Budget End
1995-09-29
Support Year
3
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Georgetown University
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Mocchetti, Italo (2011) Pharmacological regulation of gene expression. Pharmacol Res 64:323-6
McCauslin, Christine Seitz; Heath, Victoria; Colangelo, Anna Maria et al. (2006) CAAT/enhancer-binding protein delta and cAMP-response element-binding protein mediate inducible expression of the nerve growth factor gene in the central nervous system. J Biol Chem 281:17681-8
Colangelo, Anna Maria; Mallei, Alessandra; Johnson, Peter F et al. (2004) Synergistic effect of dexamethasone and beta-adrenergic receptor agonists on the nerve growth factor gene transcription. Brain Res Mol Brain Res 124:97-104
Mallei, Alessandra; Shi, Bitao; Mocchetti, Italo (2002) Antidepressant treatments induce the expression of basic fibroblast growth factor in cortical and hippocampal neurons. Mol Pharmacol 61:1017-24
Shi, B; Mocchetti, I (2000) Dexamethasone induces TrkA and p75NTR immunoreactivity in the cerebral cortex and hippocampus. Exp Neurol 162:257-67
Colangelo, A M; Follesa, P; Mocchetti, I (1998) Differential induction of nerve growth factor and basic fibroblast growth factor mRNA in neonatal and aged rat brain. Brain Res Mol Brain Res 53:218-25
Teng, Y D; Mocchetti, I; Wrathall, J R (1998) Basic and acidic fibroblast growth factors protect spinal motor neurones in vivo after experimental spinal cord injury. Eur J Neurosci 10:798-802
Shi, B; Rabin, S J; Brandoli, C et al. (1998) Dexamethasone induces hypertrophy of developing medial septum cholinergic neurons: potential role of nerve growth factor. J Neurosci 18:9326-34
Marini, A M; Rabin, S J; Lipsky, R H et al. (1998) Activity-dependent release of brain-derived neurotrophic factor underlies the neuroprotective effect of N-methyl-D-aspartate. J Biol Chem 273:29394-9
Colangelo, A M; Johnson, P F; Mocchetti, I (1998) beta-adrenergic receptor-induced activation of nerve growth factor gene transcription in rat cerebral cortex involves CCAAT/enhancer-binding protein delta. Proc Natl Acad Sci U S A 95:10920-5

Showing the most recent 10 out of 25 publications